Evidence map›Paper›PMID 26543371›Full record

ReviewTherapeutics and clinical risk management2015

Critical appraisal of extended-release hydrocodone for chronic pain: patient considerations.

Harry J Gould, Dennis Paul

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Harry J GouldDepartment of Neurology, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Department of Internal Medicine, Section of Physical Medicine and Rehabilitation, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Center of Excellence for Oral and Craniofacial Biology, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Pain Mastery Center of Louisiana, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Dennis PaulDepartment of Neurology, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Department of Internal Medicine, Section of Physical Medicine and Rehabilitation, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Center of Excellence for Oral and Craniofacial Biology, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Pain Mastery Center of Louisiana, Louisiana State University Health Sciences Center, New Orleans, LA, USA ; Alcohol and Drug Abuse Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Louisiana State University Health Sciences Center New Orleans · USPain and Rehabilitation Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioid analgesics are currently the most effective pharmacologic option for the management of both acute and chronic forms of moderate-to-severe pain. Although the "as-needed" use of immediate-release formulations is considered optimum for treating acute, painful episodes of limited duration, the scheduled dosing of extended-release formulations with immediate-release supplementation for breakthrough pain is regarded to be most effective for managing chronic conditions requiring around-the-clock treatment. The recent introduction of extended-release formulations of the opioid analgesic hydrocodone potentially broadened the possibility of providing pain relief for individuals for whom current formulations are either ineffective or not tolerated. However, reaction to the approval of the new formulations has fueled controversy over the general safety and need for opioid medications, in light of their potential for misuse, abuse, diversion, and addiction. Here, we discuss how the approval of extended-release formulations of hydrocodone and the emotionally charged controversy over their release may affect physician prescribing and the care available to patients in need of chronic opioid therapy for the management of pain.

Indexed as

addictionmisuseopioid analgesicspatient benefitspatient risks

Identifiers

PMID26543371
PMCPMC4622415
OpenAlexW2180286204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.